Drug resistance to antibiotics continues to escalate. This week we do a deep dive into the Infectious Disease Society of America’s (IDSA) brand new guidance on the treatment of antimicrobial resistant gram-negative infections.

The GameChanger: The new IDSA guidelines provide critical, evidence-based recommendations for managing drug-resistant gram-negative infections. The guidance offers health care providers clear strategies to improve outcomes and reduce the emergence of resistance.

Upon successful completion of this course, learners should be able to:
1. Identify effective strategies for treating urinary tract and systemic infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms.
2. Discuss appropriate therapeutic agents for infections caused by AmpC beta-lactamase-producing bacteria, ensuring choices minimize the risk of resistance development during treatment.

Guests
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Amanda Bushman, PharmD, BCPS-AQ ID, BCIDP, FIDSA
Infectious Disease Pharmacist
UnityPoint Health

Tony Mannum, PharmD
PGY2 Infectious Disease Resident
UnityPoint Health

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.
Neither additional speaker have any relevant financial relationships to disclose. 

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: September 2 , 2024
Planned Expiration Date: September 2 , 2025

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.